Endocrinol Metab.
2025 Feb;40(1):93-102. 10.3803/EnM.2024.2117.
Carnitine Metabolite as a Potential Circulating Biomarker for Sarcopenia in Men
- Affiliations
-
- 1Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Korea
- 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 3Biomedical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea
- 4Department of Convergence Medicine, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea
- 5Department of Orthopedic Surgery, Seoul Now Hospital, Anyang, Korea
- 6Department of Rehabilitation Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 7Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2565257
- DOI: http://doi.org/10.3803/EnM.2024.2117
Abstract
- Background
Sarcopenia, a multifactorial disorder involving metabolic disturbance, suggests potential for metabolite biomarkers. Carnitine (CN), essential for skeletal muscle energy metabolism, may be a candidate biomarker. We investigated whether CN metabolites are biomarkers for sarcopenia.
Methods
Associations between the CN metabolites identified from an animal model of sarcopenia and muscle cells and sarcopenia status were evaluated in men from an age-matched discovery (72 cases, 72 controls) and a validation (21 cases, 47 controls) cohort.
Results
An association between CN metabolites and sarcopenia showed in mouse and cell studies. In the discovery cohort, plasma C5-CN levels were lower in sarcopenic men (P=0.005). C5-CN levels in men tended to be associated with handgrip strength (HGS) (P=0.098) and were significantly associated with skeletal muscle mass (P=0.003). Each standard deviation increase in C5-CN levels reduced the odds of low muscle mass (odd ratio, 0.61; 95% confidence interval [CI], 0.42 to 0.89). The area under the receiver operating characteristic curve (AUROC) of CN score using a regression equation of C5-CN levels, for sarcopenia was 0.635 (95% CI, 0.544 to 0.726). In the discovery cohort, addition of CN score to HGS significantly improved AUROC from 0.646 (95% CI, 0.575 to 0.717; HGS only) to 0.727 (95% CI, 0.643 to 0.810; P=0.006; HGS+CN score). The improvement was confirmed in the validation cohort (AUROC=0.563; 95% CI, 0.470 to 0.656 for HGS; and AUROC=0.712; 95% CI, 0.569 to 0.855 for HGS+CN score; P=0.027).
Conclusion
C5-CN, indicative of low muscle mass, is a potential circulating biomarker for sarcopenia in men. Further studies are required to confirm these results and explore sarcopenia-related metabolomic changes.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- L-carnitine in maintenance hemodialysis clinical, lipid and biochemical effects
- Effect of L-carnitine on ischemic myocardium of Langendorff's isolated rat heart
- The effects of antiepileptic drugs on serum carnitine and liver function
- Higher Plasma Stromal Cell-Derived Factor 1 Is Associated with Lower Risk for Sarcopenia in Older Asian Adults
- Alterations in the carnitine metabolism in epileptic children treated with valproic acid
